Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Crinetics Pharmaceuticals Inc shares valued at $136,110 were sold by Betz Stephen F. on Jun 25 ’24. At $45.37 per share, Betz Stephen F. sold 3,000 shares. The insider’s holdings dropped to 80,643 shares worth approximately $3.51 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Pizzuti Dana sold 9,500 shares, netting a total of over 434,435 in proceeds. Following the sale of shares at $45.73 each, the insider now holds 27,786 shares.
Before that, Hassard James had sold 15,000 shares from its account. In a trade valued at $669,900, the Chief Commercial Officer traded Crinetics Pharmaceuticals Inc shares for $44.66 each. Upon closing the transaction, the insider’s holdings decreased to 15,000 shares, worth approximately $1.27 million.
As published in their initiating research note from Citigroup on March 06, 2024, Crinetics Pharmaceuticals Inc [CRNX] has been a Buy and the price target has been revised to $68. Analysts at Morgan Stanley started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid January. As of December 21, 2023, Jefferies has initiated its “Hold” rating for CRNX.
Analyzing CRNX Stock Performance
During the last five days, there has been a drop of approximately -1.67%. Over the course of the year, Crinetics Pharmaceuticals Inc shares have jumped approximately 22.18%. Shares of the company reached a 52-week high of $53.70 on 05/22/24 and a 52-week low of $33.67 on 01/05/24. A 50-day SMA is recorded $46.22, while a 200-day SMA reached $37.96. Nevertheless, trading volume fell to 0.69 million shares from 1.5 million shares the previous day.
Support And Resistance Levels for Crinetics Pharmaceuticals Inc (CRNX)
According to the 24-hour chart, there is a support level at 42.16, which, if violated, would cause prices to drop to 40.85. In the upper region, resistance lies at 44.24. The next price resistance is at 45.01. RSI (Relative Strength Index) is 42.37 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.46, which suggests the price will decrease in the coming days. Percent R is at 66.07%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
